Human M-CSF / CSF-1 Protein, premium grade
分子别名(Synonym)
M-CSF,CSF-1,Lanimostim
表达区间及表达系统(Source)
Human M-CSF Protein, premium grade (MCF-H5218) is expressed from human 293 cells (HEK293). It contains AA Glu 33 - Arg 255 (Accession # P09603-1).
Predicted N-terminus: Glu 33
该产品是在我们严格的质量控制体系下生产的,该体系包含一套全面的测试,包括无菌和内毒素测试。在早期临床前阶段,产品性能经过仔细验证和测试,以确保其与细胞培养用途或任何其他应用的兼容性。当准备过渡到后期临床阶段时,我们还提供定制的GMP蛋白质服务,以满足您的需求。我们将与您合作,根据您的要求定制和开发GMP级产品,该产品也符合细胞疗法细胞制造中使用的原材料和辅助材料的要求。
蛋白结构(Molecular Characterization)
This protein carries no "tag".
The protein has a calculated MW of 25.1 kDa. The protein migrates as 39 kDa±3 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
内毒素(Endotoxin)
Less than 0.01 EU per μg by the LAL method.
宿主蛋白残留(Host Cell Protein)
<0.5 ng/µg of protein tested by ELISA.
宿主核酸残留(Host Cell DNA)
<0.02 ng/μg of protein tested by qPCR.
无菌(Sterility)
Negative
支原体(Mycoplasma)
Negative.
纯度(Purity)
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
制剂(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重构方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 24 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景(Background)
集落刺激因子1(CSF1),也称为巨噬细胞集落刺激因素(M-CSF),是一种分泌的细胞因子,影响造血干细胞分化为巨噬细胞或其他相关细胞类型。真核细胞也产生M-CSF以对抗细胞间病毒感染。它是实验描述的三种集落刺激因子之一。M-CSF与集落刺激因子1受体结合。巨噬细胞集落刺激因子已被证明与PIK3R2相互作用。M-CSF(或CSF-1)是一种造血生长因子,参与单核细胞、巨噬细胞和骨髓祖细胞的增殖、分化和存活。血管壁中局部产生的M-CSF有助于动脉粥样硬化的发展和进展。
关键字: CSF-1;CSF-1蛋白;M-CSF蛋白;ACRO;百普赛斯;
百普赛斯集团ACROBiosystems Group(股票代码:301080)是成立于2010年的跨国生物科技公司,是为全球生物医药、健康产业领域提供关键生物试剂产品及解决方案的行业平台型基石企业。2021年在创业板上市。百普赛斯集团业务遍布全球,横跨亚洲、北美洲、欧洲,在中国、美国、瑞士等12个城市设有办公室、研发中心及生产基地。目前累计服务客户超6000家,与全球Top 20医药企业均建立了长期、稳定的合作伙伴关系。集团旗下拥有品牌ACROBiosystems百普赛斯、bioSeedin柏思荟、Condense Capital垦拓资本和ACRODiagnostics百斯医学等。